Norris Medicines Ltd
Norris Medicines Ltd (NORRIS) last reported results for the quarter ended Jun 2026, with sales of ₹0.92 crore and net profit of ₹-0.4 crore. The stock last traded at ₹15.8, a market capitalisation of ₹15.8 crore. Over the past 52 weeks the stock has ranged between ₹12 and ₹20.1. Figures are as of 6 Oct 2026 and are not real time.
Norris Medicines Ltd share price and key metrics
- Current price
- ₹15.8
- Market cap
- ₹15.8 cr
- Book value
- ₹-15.1
- ROE
- %
- ROCE
- 3.36%
- Dividend yield
- 0.00%
- 52w high / low
- 20.1/12.0
Metrics as of 6 Oct 2026. Not real time.
Track Norris Medicines Ltd
Cruxal reads every Norris Medicines Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Norris Medicines Ltd growth and returns
- 10 Years
- -8%
- 5 Years
- -8%
- 3 Years
- -1%
- TTM
- 16%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 23%
- TTM
- 69%
- 10 Years
- %
- 5 Years
- 9%
- 3 Years
- 9%
- 1 Year
- 2%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Norris Medicines Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.92 cr, down 37.0% from ₹1.46 cr a year earlier. Net profit was ₹-0.4 cr, down 29.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.27 | 1.11 | 2.72 | 1.46 | 2 | 3.27 | 1.41 | 0.92 |
| Expenses | 1.42 | 1.14 | 2.65 | 1.56 | 2.49 | 2.32 | 1.11 | 1.2 |
| Operating profit | -0.15 | -0.03 | 0.07 | -0.1 | -0.49 | 0.95 | 0.3 | -0.28 |
| OPM % | -11.81% | -2.70% | 2.57% | -6.85% | -24.50% | 29.05% | 21.28% | -30.43% |
| Other income | 0 | 0 | 0.05 | 0.02 | 0 | 0 | 0.02 | 0 |
| Interest | 0.08 | 0.12 | 0.15 | 0.11 | 0.11 | 0.13 | 0.15 | 0 |
| Depreciation | 0.13 | 0.13 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| Profit before tax | -0.36 | -0.28 | -0.17 | -0.31 | -0.72 | 0.7 | 0.05 | -0.39 |
| Tax % | 0.00% | 0.00% | 35.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.7 | 0.05 | -0.4 |
| EPS (₹) | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.70 | 0.05 | -0.40 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Norris Medicines Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 8.13 | 7.6 |
| Operating profit | 0 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | 0.66 | 0.48 |
| OPM % | 0.00% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | 8.12% | 6.32% |
| Net profit | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
| EPS (₹) | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
TTM is the trailing twelve months to the most recent quarter.
Norris Medicines Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.79 | -25.07 |
| Borrowings | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.40 | 21.52 | 21.58 | 21.53 |
| Other liabilities | 9.90 | 10.92 | 8.76 | 5.10 | 11.69 | 3.80 | 4.72 | 6.29 | 7.09 | 6.50 |
| Total liabilities | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
| Fixed assets | 9.97 | 9.32 | 8.90 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.27 | 4.79 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other assets | 12.06 | 11.35 | 11.47 | 12.30 | 12.10 | 7.11 | 7.20 | 8.38 | 8.53 | 8.09 |
| Total assets | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
As reported by the company. Total assets equal total liabilities by construction.
Norris Medicines Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.96 | 0.80 | -1.92 | -2.88 | 1.11 | -1.01 | 1.20 | 0.17 | 0.51 | 0.59 |
| Cash from investing | -2.05 | -0.08 | -0.29 | 0.00 | -0.06 | -0.09 | -0.02 | 0.05 | 0.00 | -0.09 |
| Cash from financing | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.10 | -1.18 | -0.20 | -0.50 | -0.52 |
| Net cash flow | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 | 0.02 | 0.00 | -0.02 |
| Free cash flow | -3.24 | 0.74 | -2.21 | -2.96 | 1.02 | -1.07 | 1.17 | 0.26 | 0.49 | 0.58 |
| CFO / operating profit | — | -42% | 315% | 133% | -63% | 1,262% | 129% | -100% | -196% | 89% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Norris Medicines Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.20% | -8.43% | -10.13% | 3.36% |
| Debtor days | 84.20 | 66.44 | 67.57 | 128.49 | 53.33 | 42.15 | 48.03 | 68.60 | 88.43 | 52.53 |
| Inventory days | 129.50 | 238.53 | 134.81 | 323.82 | 212.99 | 157.45 | 347.62 | 594.15 | 436.94 | 337.84 |
| Days payable | 125.29 | 252.40 | 139.83 | 233.37 | 218.83 | 86.53 | 149.91 | 244.25 | 320.57 | 222.40 |
| Cash conversion cycle | 88.41 | 52.56 | 62.55 | 218.94 | 47.49 | 113.06 | 245.73 | 418.51 | 204.80 | 167.97 |
| Working capital days | -16.06 | -91.18 | -32.55 | -30.73 | -103.69 | -97.82 | -122.25 | -202.56 | -240.82 | -167.46 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Norris Medicines Ltd shareholding pattern
Promoters held 34.01% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.07%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.01% | 34.00% | 34.00% | 34.00% | 34.00% | 34.00% | 34.01% | 34.01% |
| DIIs | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% |
| Public | 65.91% | 65.92% | 65.93% | 65.93% | 65.92% | 65.92% | 65.90% | 65.90% |
| No. of shareholders | 25,498 | 25,659 | 25,815 | 25,950 | 25,895 | 25,791 | 25,777 | 25,777 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Norris Medicines Ltd corporate filings
- Corporate Voting Results Confirm Approval of All Resolutions at Norris Medicines Limited AGMAGM/EGMhigh impact
Cruxal's analysis: Norris Medicines Limited held its 35th AGM on 29th September 2026 via video conferencing…
Read the full analysis - Outcome and proceeding of the 35th Annual General Meeting of the Company held on Tuesday 29th September, 2026Company Updatelow impact
- Outcome of 35th Annual General Meeting of the Company held on Tuesday, 29th September, 2026AGM/EGMmedium impact
- Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Norris Medicines Ltd announces 35th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Norris Medicines Ltd has published a newspaper advertisement regarding the scheduling of…
Read the full analysis - Norris Medicines Limited announces 35th Annual General Meeting scheduled for 29th September 2026Otherslow impact
Cruxal's analysis: Norris Medicines Limited has formally announced the convening of its 35th Annual General…
Read the full analysis - Norris Medicines Limited reports Q1 FY2027 net loss of 39.68 lakh amid declining revenue and appoints new Managing DirectorBoard Meetinghigh impact
Cruxal's analysis: Norris Medicines Limited reported a weak financial performance for the quarter ended June…
Read the full analysis - Norris Medicines Limited schedules Board Meeting for June 2026 quarterly resultsBoard Meetinglow impact
Cruxal's analysis: Norris Medicines Limited has issued a formal intimation regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.